MedTrace Logo

24-hr Intraocular Pressure Control With SIMBRINZA ®

NCT02770248 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2018-07-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate differences between treatments in mean change from baseline in 24-hr intraocular pressure (IOP) at Week 4.

Conditions

Interventions

DRUG

Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension

DRUG

Vehicle

Inactive ingredients used as a placebo for masking purposes

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Clinical Manager, GCRA · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-23
Primary Completion
2017-01-14
Completion
2017-01-14

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02770248 on ClinicalTrials.gov